Medtech M&A Picked Up in 2024, But Belt-Tightening Continues

After a sluggish 2023, medtech M&A rallied this year to deliver a modest increase in deal activity. Inflation eased slightly, which inspired new activity. Also, the impact of GLP-1 drugs was not as dramatic as some feared, and dealmakers may have adjusted to a climate of higher-than-near-zero interest rates.